Jaguar Health, Inc. Q4 FY2024 earnings call

• Lisa Conte, Founder, President, and CEO, provided an overview of Jaguar Health's financial performance and ongoing efforts. 2024 net revenue increased 20% versus 2023. - Bridge financing was announced with participation from board members, executives, and investors, with catalysts expected in Q2 2025 and throughout 2025. - Discussed the intestinal failure rare disease program, including MVID and SBS-IF, with ongoing trials and potential PRIME designation from EMA. - Mytesi, the FDA-approved product for HIV and AIDS-related diarrhea, had a Phase 3 on-target clinical trial for cancer patients, with a Type C face-to-face meeting with FDA expected in Q2 2025. - Gelclair, the oral mucositis prescription product, is being launched into specific medical centers, with future expansion planned. - Canalevia-CA1 is available for chemotherapy-induced diarrhea in dogs, a relevant model for human situations.

Total net revenue for 2024 was approximately $11.7 million, representing a 20% increase versus 2023's net revenue of approximately $9.8 million. In Q4 2024, total net revenue was approximately $3.5 million, a 13% increase from Q3 2024's $3.1 million and a 53% increase from Q4 2023's $2.3 million. Mytesi prescription volume increased approximately 3.9% in 2024 compared to 2023, with a 3.4% increase in Q4 2024 versus Q3 2023 and a 9.4% increase in Q4 2024 versus Q4 2023. Loss from operations decreased from $34.3 million in 2023 to $30.8 million in 2024. Non-GAAP recurring EBITDA for 2024 was a net loss of $34.7 million, similar to the $34.5 million net loss in 2023. Net loss attributable to common shareholders decreased from $41.3 million in 2023 to $38.5 million in 2024.

• Multiple near-term catalysts are expected in Q2 2025 and throughout 2025, including potential collaborations, business development, and licensing deals to support bringing late-stage products to regulatory approval and patient access. - Catalysts for the intestinal failure rare disease program and Mytesi program are seen as significant and value-enhancing.

• Forward-looking statements are subject to risks and uncertainties that can cause actual results to differ materially from contemplated statements. - Non-GAAP financial measures should not be viewed in isolation or as substitutes for GAAP measures. - Risks related to market acceptance of products, competitive products and pricing, industry trends, and regulatory requirements for product initiatives.

Q: None A: None